Treatment of diffuse large B-cell lymphoma (DLBCL) with the HDAC inhibitor panobinostat (LBH589) results in STAT3 hyperacetylation, dephosphorylation and increased nuclear export, inhibiting the transcription of STAT3-responsive anti-apoptotic genes and the survival of DLBCL cells44. The gene discussed is HDAC9; the disease is diffuse large B-cell lymphoma.